Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Pure Global Cannabis Inc. (PRCNF)
Toronto, ON, CA
Operating from Toronto, Canada, Pure Global Cannabis Inc. specializes in the creation and distribution of diverse cannabis products across Canadian medical and adult recreational sectors. Its extensive inventory includes dried cannabis flower, various oils, soft gels, capsules, foundational items like seedlings and clones, vape cartridges, topical applications, sublingual delivery systems (strips/sprays), transdermal patches, and a selection of infused edibles and beverages, along with broader wellness offerings. These goods are retailed under distinct brand names such as PureSinse, SPARK Medical Cannabis clinics, and The Great Canadian Hemp Company. The firm caters to a wide range of industries, including medical, pharmaceutical, wellness, health and beauty, natural health, food and beverage, and the regulated recreational markets.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +900.00% | +0.00% | -99.83% | -100.00% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%—
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-905.9%
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%—
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%—
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%-172.7%
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+93.7%
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×-0.52×
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Malay Panchal | Founder, President, Chief Executive Officer, Treasurer & Director | 2M | male |
| Bhupender Gosain | Chief Financial Officer & Corporate Secretary | 106.1K | male |
| Michael Lavergne | Head of Global Supply Chain Services | — | male |
| Stephen Pynn | Vice President of Corporate Development | — | male |
| Trupti Smit | Director of Corporation & Legal Affairs | — | female |
| Mee Kiat Wong | Company Secretary | — | — |
| Li Heong Lim | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PRCNF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
